You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

Why pair TIVICAY and Lamivudine?

The Next Step in the 2-Drug Regimen Era

Go To Top Close

A complete regimen of just 2 pills powered by dolutegravir at the core

Like traditional 3-drug regimens, DTG + 3TC inhibits the viral life cycle at 2 different targets

  • Has shown statistically superior efficacy vs 5 different ART comparators when evaluated in traditional 3-drug regimens 1-5
  • Is proven effective in 2-drug regimens with lamivudine in treatment-naïve adult patients at 48 weeks and rilpivirine in virologically suppressed patients at 100 weeks 6 7
  • An INI with a high barrier to resistance proven in clinical trials up to 144 weeks 1-8
  • Favourable drug-drug interaction profile 9
  • Generally well tolerated 1-3
  • Rapid and sustained response in treatment-naïve patients 9 10
  • Over 20 years of experience 11
  • Established efficacy and generally well tolerated 12-15
  • Few clinically significant drug-drug interactions 12 16
  • Guidelines recommended since 1998 17-22


Tivicay + lamivudine is only suitable for the treatment of HIV-1 infection where there is no known or suspected resistance to the integrase inhibitor class, or to lamivudine.
 

References:

  1. Walmsley S et al. J Acquir Immune DeficSyndr. 2015;70:515-519.
  2. Molina J-M et al. Lancet HIV. 2015;2(4):e127-e136.
  3. Orrell C et al. Lancet HIV. 2017;4:e536-e546.
  4. Cahn P et al. Lancet. 2013;382(9893):700-708.
  5. Aboud M et al. International AIDS Conference, July 23-27, 2018; Amsterdam, Netherlands. Poster THPEB040
  6. Cahn P et al. International AIDS Conference; July 23-27, 2018; Amsterdam, Netherlands.
  7. Aboud M et al. International AIDS Conference; Jult 23-27, 2018; Amsterdam, Netherlands. Poster THPEB047
  8. Trottier B et al. Antivir Ther. 2017;22:295-305
  9. Min S et al. AIDS. 2011;25:1737-1745
  10. van Lunzen J et al. Lancet Infect Dis. 2012;12(2):111-118.
  11. Antiretroviral drugs used in the treatment of HIV infection. https://www.fda.gov/ForPatients/Illness/HIVAIDS/Treatment/ucm118915.htm. Accessed November 2018.
  12. Quercia R et al. J Acquir Immune Defic Syndr. 2018;78(2):125-135.
  13. Eron JJ. AIDS. 1996:5;S11-S19.
  14. Bartlett JA et al. Ann Intern Med. 1996:125(3);161-172.
  15. Result summary for NUCB3001. Research Triangle Park, NC. ViiV Healthcare group of companies; September 2, 2005. https://viiv-clinicalstudyregister.com/files2/1561.pdf. Accessed November 2018.
  16. Epivir Summary of Product Characteristics.
  17. US Department of Health and Human Services. Report of the NIH panel to define principles of therapy of HIV infection and guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents; April 24, 1998. https://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL04241998014.pdf. Accessed November 2018.
  18. Carpenter CCJ et al. JAMA. 1998;280(1):78-86.
  19. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. May 30, 2018. https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf. Accessed November 2018
  20. Saag MS et al. JAMA. 2018;320(4):379-396.
  21. European AIDS Clinical Society. Guidelines. Version 9.0. October 2017. http://www.eacsociety.org/files/guidelines_9.0-english.pdf. Accessed November 2018.
  22. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Second edition, 2016. Accessed November 2018.

▼ These medicinal products are subject to additional monitoring. This will allow quick identification of new safety information.
Healthcare professionals are asked to report any suspected adverse reactions.

Trademarks are owned by or licensed to the ViiV Healthcare group of companies.

Adverse events should be reported directly to the HPRA; Freepost, Pharmacovigilance Section, Health Products Regulatory Authority, Earlsfort Terrace, Dublin 2, Tel: +353 1 676 4971 medsafety@hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.